Hydrophilic vehicle-based dual controlled release matrix system

• US 8,333,989 B2
• Filed: 10/26/2006
• Issued: 12/18/2012
• Est. Priority Date: 10/26/2005
• Status: Expired due to Fees

• Current Assignee: Patheon Softgels, Inc. (Thermo Fisher Scientific Incorporated)
• Original Assignee: Banner Pharmacaps Incorporated (Thermo Fisher Scientific Incorporated)
• Inventors: Sukuru, Karunakar
• Primary Examiner(s): Richter, Johann
• Assistant Examiner(s): KASSA, JESSICA M
• Application Number:
  US11/553,356
• Publication Number:
  US 20070098783A1
• Time in Patent Office: 2,245 Days
• Field of Search: None
• US Class Current: 424/452
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds

Abstract

A hydrophilic vehicle-based dual controlled-release matrix system, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a solution or a suspension, which allows for easier formulation of low dose compounds. The matrix includes two rate controlling barriers for the controlled release of one or more pharmaceutically active agents. The primary rate controlling barrier includes a hydrophilic vehicle. The primary rate controlling barrier can further comprise one or more solvents which are miscible with the hydrophilic vehicle. The secondary rate controlling barrier includes a hydrogel-forming polymeric material dissolved or dispersed in the hydrophilic vehicle. The presence of the hydrogel-forming polymeric material makes extraction of the drug from the dosage form more difficult. This feature could be beneficial in preventing or minimizing the misuse of dosage forms which contain drugs which are prone to abuse.

Claims

1. A capsule comprising a dual controlled release liquid matrix, the matrix comprising:

(a) a primary rate-controlling barrier comprising a hydrophilic vehicle;

(b) a secondary rate-controlling barrier comprising a hydrogel-forming polymeric material dissolved or dispersed in the hydrophilic vehicle; and

(c) a therapeutic, prophylactic or diagnostic agent dissolved or dispersed within the liquid matrix,

wherein when the liquid matrix comes in contact with an aqueous medium, the hydrogel forming material forms a hydrogel suspended in the hydrophilic vehicle, and

wherein the release of the therapeutic, prophylactic, or diagnostic agent is biphasic.

2. The capsule of claim 1, wherein the secondary rate-controlling barrier is dissolved or dispersed in the primary rate-controlling barrier.

3. The capsule of claim 1, wherein the hydrophilic vehicle is selected from the group consisting of polyethylene glycol, polyoxyethylene 32 lauric glyceride, polyoxyethylene 8 caprylic/capric glyceride, glycofurol and polysorbate.

4. The capsule of claim 1, wherein the hydrophilic vehicle is present in an amount from about 10 to about 80% by weight of the matrix.

5. The capsule of claim 4, wherein the hydrophilic vehicle is present in an amount from about 20 to about 60% by weight of the matrix.

6. The capsule of claim 1, further comprising one or more solvents miscible with the hydrophilic vehicle.

7. The capsule of claim 6, where in the one or more miscible solvents is selected from the group consisting of glycerin, propylene glycol, ethanol, glycofurol and macrogol 8-glyceride.

8. The capsule of claim 6, wherein the one or more miscible solvents is present in an amount from about 1% to about 80% by weight of the fill material.

9. The capsule of claim 1, wherein the hydrogel-forming polymeric material is selected from the group consisting of cellulose ethers, cross-linked acrylates, alginates, guar, xanthan gum, carrageenan, carboxymethyl cellulose, high molecular weight polypyrrolidone, and mixtures thereof.

10. The capsule of claim 1, wherein the hydrogel-forming polymeric material is present in an amount from about 3% to about 80% by weight of the matrix.

11. The capsule of claim 10, wherein the hydrogel-forming polymeric material is present in an amount from about 5% to about 50% by weight of the matrix.

12. The capsule of claim 1, wherein the therapeutically, prophylactic, and diagnostic agent is selected from the group consisting of analeptic agents;

analgesic agents;

anesthetic agents;

antiasthmatic agents;

antiarthritic agents;

anticancer agents;

anticholinergic agents;

anticonvulsant agents;

antidepressant agents;

antidiabetic agents;

antidiarrheal agents;

antiemetic agents;

antihelminthic agents;

antihistamines;

antihyperlipidemic agents;

antihypertensive agents;

anti-infective agents;

anti-inflammatory agents;

antimigraine agents;

antineoplastic agents;

antiparkinson drugs;

antipruritic agents;

antipsychotic agents;

antipyretic agents;

antispasmodic agents;

antitubercular agents;

antiulcer agents;

antiviral agents;

anxiolytic agents;

appetite suppressants;

attention deficit disorder and attention deficit hyperactivity disorder drugs;

cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system agents, beta-blockers and antiarrhythmic agents;

central nervous system stimulants;

diuretics;

genetic materials;

hormonolytics;

hypnotics;

hypoglycemic agents;

immunosuppressive agents;

muscle relaxants;

narcotic antagonists;

nicotine;

nutritional agents;

parasympatholytics;

peptide drugs;

psychostimulants;

sedatives;

sialagogues, steroids;

smoking cessation agents;

sympathomimetics;

tranquilizers;

vasodilators;

beta-agonist;

tocolytic agents, and combinations thereof.

13. The capsule of claim 1, wherein the therapeutic, prophylactic or diagnostic agent is a drug prone to abuse.

14. The capsule of claim 1, wherein the capsule is selected from the group consisting of soft gelatin capsules, hard gelatin capsules, and non-gelatin soft capsules.

15. The capsule of claim 1, wherein the release of the therapeutic, prophylactic or diagnostic agent is modulated for up to 24 hours.